Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04618744 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH)
A Phase 2 study, sponsored by Oramed.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT04618744 is a Phase 2 study that has completed, run by Oramed. The registered enrollment target is 32 participants.
The verdict
NCT04618744, a Phase 2 study, has completed, sponsored by Oramed.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a double-blind, randomized, placebo-controlled, multi-center study using the oral ORMD-0801 insulin formulation in patients with NASH and confirmed type 2 DM.
Interventions
- OTHER Placebo
- DRUG ORMD-0801 (Insulin) capsule 8 mg BD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2020-11-24 |
| Est. Completion | 2022-06-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04618744
The ClinicalTrials.gov registry entry for NCT04618744 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oramed, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04618744 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04618744 about?
NCT04618744 is a clinical study titled "A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH)". This is a double-blind, randomized, placebo-controlled, multi-center study using the oral ORMD-0801 insulin formulation in patients with NASH and confirmed type 2 DM.
What is the current status of trial NCT04618744?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2020-11-24. Estimated completion is 2022-06-27.
What interventions are being tested in trial NCT04618744?
The interventions under investigation include: Placebo (OTHER), ORMD-0801 (Insulin) capsule 8 mg BD (DRUG).
Who is sponsoring clinical trial NCT04618744?
This trial is sponsored by Oramed, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.